IBO (Impact BioMedical) Debt-to-Equity : 0.26 (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Impact BioMedical Debt-to-Equity?

Impact BioMedical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.04 Mil. Impact BioMedical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $7.97 Mil. Impact BioMedical's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $31.35 Mil. Impact BioMedical's debt to equity for the quarter that ended in Sep. 2024 was 0.26.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Impact BioMedical's Debt-to-Equity or its related term are showing as below:

IBO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.37 Max: 1.21
Current: 0.26

During the past 5 years, the highest Debt-to-Equity Ratio of Impact BioMedical was 1.21. The lowest was 0.03. And the median was 0.37.

IBO's Debt-to-Equity is ranked worse than
60.92% of 1021 companies
in the Biotechnology industry
Industry Median: 0.15 vs IBO: 0.26

Impact BioMedical Debt-to-Equity Historical Data

The historical data trend for Impact BioMedical's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Impact BioMedical Debt-to-Equity Chart

Impact BioMedical Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.03

0.34

0.48

Impact BioMedical Quarterly Data
	Sep19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															0.44	0.48	0.53	0.58	0.26

Competitive Comparison of Impact BioMedical's Debt-to-Equity

For the Biotechnology subindustry, Impact BioMedical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Impact BioMedical's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Impact BioMedical's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Impact BioMedical's Debt-to-Equity falls into.

Impact BioMedical Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Impact BioMedical's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(12.074	+	0)	/	25.222
	=	0.48

Impact BioMedical's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.035	+	7.971)	/	31.348
	=	0.26

Impact BioMedical (AMEX:IBO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Impact BioMedical Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Impact BioMedical's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Impact BioMedical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Impact BioMedical Inc (AMEX:IBO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Wiregrass Parkway, West Henrietta, NY, USA, 14586

Website

https://www.impactbiomedinc.com

Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.

Impact BioMedical Headlines

From GuruFocus

DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value

By Marketwired • 09-16-2024